Literature DB >> 34760976

The upward trend in the immunotherapy utilization for hepatobiliary cancers.

Xiao-Bu Lan1, George Papatheodoridis2, Yu-Xian Teng3, Jian-Hong Zhong3.   

Abstract

Entities:  

Year:  2021        PMID: 34760976      PMCID: PMC8527408          DOI: 10.21037/hbsn-21-342

Source DB:  PubMed          Journal:  Hepatobiliary Surg Nutr        ISSN: 2304-3881            Impact factor:   7.293


× No keyword cloud information.
  12 in total

1.  Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.

Authors:  Richard S Finn; Shukui Qin; Masafumi Ikeda; Peter R Galle; Michel Ducreux; Tae-You Kim; Masatoshi Kudo; Valeriy Breder; Philippe Merle; Ahmed O Kaseb; Daneng Li; Wendy Verret; Derek-Zhen Xu; Sairy Hernandez; Juan Liu; Chen Huang; Sohail Mulla; Yulei Wang; Ho Yeong Lim; Andrew X Zhu; Ann-Lii Cheng
Journal:  N Engl J Med       Date:  2020-05-14       Impact factor: 91.245

2.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.

Authors:  Hyuna Sung; Jacques Ferlay; Rebecca L Siegel; Mathieu Laversanne; Isabelle Soerjomataram; Ahmedin Jemal; Freddie Bray
Journal:  CA Cancer J Clin       Date:  2021-02-04       Impact factor: 508.702

3.  Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.

Authors:  Anthony B El-Khoueiry; Bruno Sangro; Thomas Yau; Todd S Crocenzi; Masatoshi Kudo; Chiun Hsu; Tae-You Kim; Su-Pin Choo; Jörg Trojan; Theodore H Welling; Tim Meyer; Yoon-Koo Kang; Winnie Yeo; Akhil Chopra; Jeffrey Anderson; Christine Dela Cruz; Lixin Lang; Jaclyn Neely; Hao Tang; Homa B Dastani; Ignacio Melero
Journal:  Lancet       Date:  2017-04-20       Impact factor: 79.321

4.  Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial.

Authors:  Richard S Finn; Baek-Yeol Ryoo; Philippe Merle; Masatoshi Kudo; Mohamed Bouattour; Ho Yeong Lim; Valeriy Breder; Julien Edeline; Yee Chao; Sadahisa Ogasawara; Thomas Yau; Marcelo Garrido; Stephen L Chan; Jennifer Knox; Bruno Daniele; Scot W Ebbinghaus; Erluo Chen; Abby B Siegel; Andrew X Zhu; Ann-Lii Cheng
Journal:  J Clin Oncol       Date:  2019-12-02       Impact factor: 44.544

5.  Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.

Authors:  Zhenggang Ren; Jianming Xu; Yuxian Bai; Aibing Xu; Shundong Cang; Chengyou Du; Qiu Li; Yinying Lu; Yajin Chen; Yabing Guo; Zhendong Chen; Baorui Liu; Weidong Jia; Jian Wu; Junye Wang; Guoliang Shao; Bixiang Zhang; Yunfeng Shan; Zhiqiang Meng; Jianbing Wu; Shanzhi Gu; Wei Yang; Chao Liu; Xuetao Shi; Zhenyuan Gao; Tao Yin; Jiuwei Cui; Ming Huang; Baocai Xing; Yilei Mao; Gaojun Teng; Yanru Qin; Jinhai Wang; Feng Xia; Guowen Yin; Yong Yang; Mingxia Chen; Yan Wang; Hui Zhou; Jia Fan
Journal:  Lancet Oncol       Date:  2021-06-15       Impact factor: 41.316

6.  Disparities of Immunotherapy Utilization in Patients with Stage III Cutaneous Melanoma: A National Perspective.

Authors:  Zaid Al-Qurayshi; Jason E Crowther; John B Hamner; Christopher Ducoin; Mary T Killackey; Emad Kandil
Journal:  Anticancer Res       Date:  2018-05       Impact factor: 2.480

7.  Tumor stage and primary treatment of hepatocellular carcinoma at a large tertiary hospital in China: A real-world study.

Authors:  Jian-Hong Zhong; Ning-Fu Peng; Xue-Mei You; Liang Ma; Xiao Xiang; Yan-Yan Wang; Wen-Feng Gong; Fei-Xiang Wu; Bang-De Xiang; Le-Qun Li
Journal:  Oncotarget       Date:  2017-03-14

8.  NASH limits anti-tumour surveillance in immunotherapy-treated HCC.

Authors:  Dominik Pfister; Nicolás Gonzalo Núñez; Roser Pinyol; Olivier Govaere; Matthias Pinter; Marta Szydlowska; Revant Gupta; Mengjie Qiu; Aleksandra Deczkowska; Assaf Weiner; Florian Müller; Ankit Sinha; Ekaterina Friebel; Thomas Engleitner; Daniela Lenggenhager; Anja Moncsek; Danijela Heide; Kristin Stirm; Jan Kosla; Eleni Kotsiliti; Valentina Leone; Michael Dudek; Suhail Yousuf; Donato Inverso; Indrabahadur Singh; Ana Teijeiro; Florian Castet; Carla Montironi; Philipp K Haber; Dina Tiniakos; Pierre Bedossa; Simon Cockell; Ramy Younes; Michele Vacca; Fabio Marra; Jörn M Schattenberg; Michael Allison; Elisabetta Bugianesi; Vlad Ratziu; Tiziana Pressiani; Antonio D'Alessio; Nicola Personeni; Lorenza Rimassa; Ann K Daly; Bernhard Scheiner; Katharina Pomej; Martha M Kirstein; Arndt Vogel; Markus Peck-Radosavljevic; Florian Hucke; Fabian Finkelmeier; Oliver Waidmann; Jörg Trojan; Kornelius Schulze; Henning Wege; Sandra Koch; Arndt Weinmann; Marco Bueter; Fabian Rössler; Alexander Siebenhüner; Sara De Dosso; Jan-Philipp Mallm; Viktor Umansky; Manfred Jugold; Tom Luedde; Andrea Schietinger; Peter Schirmacher; Brinda Emu; Hellmut G Augustin; Adrian Billeter; Beat Müller-Stich; Hiroto Kikuchi; Dan G Duda; Fabian Kütting; Dirk-Thomas Waldschmidt; Matthias Philip Ebert; Nuh Rahbari; Henrik E Mei; Axel Ronald Schulz; Marc Ringelhan; Nisar Malek; Stephan Spahn; Michael Bitzer; Marina Ruiz de Galarreta; Amaia Lujambio; Jean-Francois Dufour; Thomas U Marron; Ahmed Kaseb; Masatoshi Kudo; Yi-Hsiang Huang; Nabil Djouder; Katharina Wolter; Lars Zender; Parice N Marche; Thomas Decaens; David J Pinato; Roland Rad; Joachim C Mertens; Achim Weber; Kristian Unger; Felix Meissner; Susanne Roth; Zuzana Macek Jilkova; Manfred Claassen; Quentin M Anstee; Ido Amit; Percy Knolle; Burkhard Becher; Josep M Llovet; Mathias Heikenwalder
Journal:  Nature       Date:  2021-03-24       Impact factor: 49.962

9.  Immunotherapy utilization for hepatobiliary cancer in the United States: disparities among patients with different socioeconomic status.

Authors:  Kota Sahara; S Ayesha Farooq; Diamantis I Tsilimigras; Katiuscha Merath; Anghela Z Paredes; Lu Wu; Rittal Mehta; J Madison Hyer; Itaru Endo; Timothy M Pawlik
Journal:  Hepatobiliary Surg Nutr       Date:  2020-02       Impact factor: 7.293

Review 10.  Immunotherapy for cholangiocarcinoma: a 2021 update.

Authors:  Nikolaos Charalampakis; Georgios Papageorgiou; Sergios Tsakatikas; Rodanthi Fioretzaki; Christo Kole; Stylianos Kykalos; Maria Tolia; Dimitrios Schizas
Journal:  Immunotherapy       Date:  2021-06-30       Impact factor: 4.196

View more
  1 in total

1.  Repeat hepatic resection versus percutaneous ablation for the treatment of recurrent hepatocellular carcinoma: meta-analysis.

Authors:  Bao-Hong Yuan; Yan-Kun Zhu; Xu-Ming Zou; Hao-Dong Zhou; Ru-Hong Li; Jian-Hong Zhong
Journal:  BJS Open       Date:  2022-03-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.